Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories has launched Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of Diprivan (propofol) Injectable Emulsion, USP, approved by the US Food and Drug Administration (USFDA).

According to IMS Health, the Diprivan brand and generic had U.S. sales of approximately $310 million MAT for the most recent twelve months ending in November 2018. The company's Propofol Injectable Emulsion, USP is available in 10 mg/ml vials for single patient use only. 

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.